-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical announced that the company received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for the new indications of hichrapopa ethanolamine tablets was accepted. The proposed indications are adult patients with chronic liver disease-related thrombocytopenia who intend to undergo aggressive surgery at elective dates. The report was based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial. The study reached the main study end point, and the trial group was significantly superior to the control group in terms of main efficacy endpoints. Up to now, this drug-related project has invested about 668 million yuan in R&D.

Zhitongcaijing·11/20/2026 08:57:06
Listen to the news
Hengrui Pharmaceutical announced that the company received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for the new indications of hichrapopa ethanolamine tablets was accepted. The proposed indications are adult patients with chronic liver disease-related thrombocytopenia who intend to undergo aggressive surgery at elective dates. The report was based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial. The study reached the main study end point, and the trial group was significantly superior to the control group in terms of main efficacy endpoints. Up to now, this drug-related project has invested about 668 million yuan in R&D.